All in all, our findings may be of importance for future personalized preventive treatment strategies for patients receiving a TIPS by adding a new blood‐based biomarker in NfL to other established risk factors, such as poorer liver function or sarcopenia [4]. This evidence concerns the gene NEFL and sarcopenia.